Three heads are better than one: OpenAI, Formation Bio and Sanofi collaborate to advance drug development

Many hands make light work, especially when one of those hands involves powerful artificial intelligence (AI). Three teams—Sanofi (Paris, France), Formation Bio (NY, USA) and OpenAI (CA, USA)—have come together in the hope to transform the landscape of drug development and accelerate the delivery of new medicines to patients.

The collaboration will harness the combined strengths of the three companies, merging proprietary data, advanced software, and finely-tuned AI models to create bespoke solutions for every stage of the drug development process. Sanofi, a global healthcare leader, aims to leverage this partnership to become the first biopharma company powered by AI on a large scale.

Paul Hudson, CEO of Sanofi, highlighted the significance of this alliance, stating, “This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.”

You may also be interested in:

• Past, present and future of quantitative drug discovery practices
• In the Zone: the importance of tailored sample preparation methods
• FDA-approved AI-driven tool for sepsis diagnosis

OpenAI, renowned for its AI technology, will provide access to its advanced capabilities and resources, including model fine-tuning and deep AI expertise.

Brad Lightcap, COO of OpenAI, is enthusiastic for the project: “There is massive potential for AI to accelerate drug development. We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market.”

Formation Bio, an AI-driven pharma company, will contribute its extensive engineering resources and tech-driven development platform to the partnership.

Benjamine Liu, Co-Founder and CEO of Formation Bio, stated, “I firmly believe that by combining our strengths, Sanofi, OpenAI and Formation Bio can reimagine drug development in the pharma industry. By creating and implementing customized AI agents and models designed for our industry, companies like Sanofi and Formation Bio can begin to scale with unprecedented productivity and transform the pace at which we bring new medicines to patients.”